Cyclerion Therapeutics is Drug Discovery in United States that focus on Cyclerion Therapeutics Inc business. Founded in 2019. They cover business area such as Cyclerion Therapeutics Inc, soluble guanylate cyclase (sGC) pharmacology, breakthrough treatment, serious and orphan disease, its focus, next-generation sgc stimulator, its pipeline product, Olinciguat, Praliciguat.
2019
( 5 years old in 2024 )
Cyclerion Therapeutics Inc
-
245 First Street
Riverview II, 18th Floor
Cambridge, MA 02142
United States
Private
Cyclerion Therapeutics Incsoluble guanylate cyclase (sGC) pharmacologybreakthrough treatmentserious and orphan diseaseits focusnext-generation sgc stimulatorits pipeline productOlinciguatPraliciguat
* We use standard office opening hours in near Cyclerion Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Cyclerion Therapeutics is Drug Discovery business from United States that founded in 2019 (5 years old in 2024), Cyclerion Therapeutics business is focusing on Cyclerion Therapeutics Inc.
Cyclerion Therapeutics headquarter office and corporate office address is located in 245 First Street Riverview II, 18th Floor Cambridge, MA 02142 United States.
Cyclerion Therapeutics was founded in United States.
In 2024, Cyclerion Therapeutics is currently focus on Cyclerion Therapeutics Inc sector.
Above is snippet of Google Trends for "Cyclerion Therapeutics Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Cyclerion Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
